Aug. 30 Quick Takes: Pfizer’s abrocitinib beats Dupixent in atopic dermatitis Phase III

Pfizer Inc. (NYSE:PFE) said JAK-1 inhibitor abrocitinib was superior to marketed therapy Dupixent dupilumab, an IL-4R and IL-13 inhibitor from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NASDAQ:SNY), across primary and secondary endpoints in the Phase III JADE DARE trial to treat adults with atopic dermatitis. Detailed data will be presented at future scientific meeting. Abrocitinib is a once-daily oral therapy, whereas Dupixent is a subcutaneous injection given either every two or four weeks. 

Last week, the European Commission approved JAK-1 inhibitor Rinvoq upadacitinib from AbbVie Inc. (NYSE:ABBV) for adolescents and adults with atopic dermatitis. Rinvoq has produced some of the highest response rates of coming competitors to Dupixent...